Key result
Pemafibrate XR lowers LDL-C by up to ~25% vs. placebo at 12 weeks.
Why the study?
Does pemafibrate extended-release reduce LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels?
RCT (n=71)
double-blind
randomized
Yes
Does pemafibrate extended-release reduce LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels?
Pemafibrate extended-release significantly reduces LDL-C in statin-intolerant patients with hypercholesterolemia and normal triglycerides, offering a potential alternative lipid-lowering therapy.
Answers are grounded in this paper and cite their sources.
Expands LDL-C lowering options for statin-intolerant patients; extends pemafibrate evidence beyond triglyceride lowering.
BACKGROUND: Management of low-density lipoprotein cholesterol (LDL-C) in patients with statin intolerance requires treatment options beyond statins. Pemafibrate, primarily used to lower serum triglycerides in patients with hypertriglyceridemia, has also been reported in some clinical trials to reduce LDL-C. OBJECTIVE: To evaluate the efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia. METHODS: In this phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, patients with statin-intolerant hypercholesterolemia and normal triglyceride levels were enrolled. The primary endpoint was the percentage change in calculated LDL-C from baseline to week 12. RESULTS: Seventy-one patients were randomly assigned to receive placebo or the extended-release (XR) formulation of pemafibrate at 0.2 mg/d or 0.4 mg/d. LDL-C decreased significantly from baseline in the pemafibrate groups (least squares mean [95% CI]: -20.0% [-24.1 to -15.9] for XR 0.2 mg/d; -24.8% [-28.8 to -20.9] for XR 0.4 mg/d), demonstrating superiority over placebo (-0.4% [-4.2 to 3.5]). Reductions in apolipoprotein B were also greater in the pemafibrate groups than in the placebo group (least squares mean; -18.2% for XR 0.2 mg/d; -20.6% for XR 0.4 mg/d; P < .001 vs placebo). Treatment-emergent adverse events were generally similar across groups, though slightly more frequent in the pemafibrate groups (47.8% for XR 0.2 mg/d and 54.2% for XR 0.4 mg/d) than in the placebo group (37.5%). CONCLUSION: Pemafibrate effectively and safely reduces LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels, offering a potential new therapeutic option for this population.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2026) conducted an RCT in statin-intolerant hypercholesterolemia (n=71). Pemafibrate extended-release vs. Placebo was evaluated on percentage change in calculated LDL-C from baseline to week 12. Pemafibrate extended-release demonstrated superiority over placebo in reducing LDL-C at 12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: